AbbVie Strikes $100B Pricing-Manufacturing Deal, Forecasts $67B 2026 Revenue
AbbVie struck a $100B agreement that ties future drug pricing to onshore manufacturing objectives. The company projects 2026 revenues of $67B, led by Rinvoq and Skyrizi growth, with neuroscience gains offsetting Humira erosion and mitigating oncology headwinds.
1. $100B Deal Links Pricing to Local Manufacturing
AbbVie agreed to a $100 billion arrangement aligning its branded drug pricing with domestic manufacturing goals, intending to secure supply chain resilience and access potential incentives tied to onshore production.
2. 2026 Revenue Forecast at $67B
The company now expects full-year 2026 revenues of $67 billion, reflecting strategic price adjustments and volume gains under the new deal as Humira sales continue to decline.
3. Growth Drivers and Headwinds
Key growth will come from accelerating uptake of Rinvoq and Skyrizi and gains in neuroscience, while Humira erosion and continued oncology challenges may moderate overall revenue expansion.